China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round, securing an investment exceeding RMB 100 million. The funding round was led by V-Capital, Shengze Investment, Sunbow Capital, and VVB Fund. The capital raised will be strategically allocated to accelerate the company’s multiple clinical studies for eye disease drugs, bolster pre-clinical pipeline development, and expand its technology platform.
Focus on Ophthalmology Research and Development
VivaVision is dedicated to research and development within the ophthalmology field, offering a comprehensive product pipeline that addresses various eye conditions. The pipeline includes treatments for dry eye, glaucoma, uveitis, and other eye diseases. The company’s innovative approach is exemplified by its three key products: VVN001 for dry eye treatment, VVN539, the world’s first dual target small molecule drug for glaucoma treatment, and VVN461 for non-infectious anterior segment uveitis and postoperative inflammation.
Encouraging Phase II Clinical Trial Results for VVN001
VVN001, a significant product in VivaVision’s pipeline, has successfully concluded Phase II clinical trials in both China and the US, yielding encouraging results. This progress underscores the potential of VivaVision’s products to make a substantial impact in the treatment of eye diseases.-Fineline Info & Tech
